RT Journal Article
SR Electronic
T1 Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1063
OP 1068
DO 10.21873/anticanres.14863
VO 41
IS 2
A1 AKIMITSU YAMADA
A1 KYOKO NAKAZAWA
A1 KOHEI AKAZAWA
A1 KAZUTAKA NARUI
A1 ITARU ENDO
A1 YOSHIE HASEGAWA
A1 NORIO KOHNO
A1 TAKASHI ISHIKAWA
A1 THE JONIE STUDY GROUP
YR 2021
UL http://ar.iiarjournals.org/content/41/2/1063.abstract
AB Background/Aim: We evaluated the impact of the relative dose intensity (RDI) of neoadjuvant chemotherapy (NAC) on the survival of patients with breast cancer (BC). Patients and Methods: This randomized phase II trial included 188 patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with anthracycline followed by paclitaxel as NAC. We grouped patients using a relative dose intensity (RDI) threshold of 85% and evaluated clinicopathological features and clinical outcomes. Results: The 5-year overall survival rate was 91.2% and 76.3%, when RDI ≥85% and <85%, respectively (p=0.015). Age, tumor, and node status, and the RDI were significantly different on univariate analysis, but not on multivariate analysis. An exploratory subgroup analysis revealed that a low RDI was associated with low overall survival of patients with obesity, T1/2 disease, and lymph node metastases. Conclusion: Maintaining the RDI of NAC is crucial for achieving the survival benefit in selected patients with HER2-negative BC.